Dime Community Bancshares, Inc. Reports Strong Third Quarter 2022 Results Robust Quarterly Loan Originations and Net Interest Margin Expansion Drive Net Interest Income Growth HAUPPAUGE, N.Y., Oct. 28, 2022 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), today reported net income…

Have You Heard the Latest Buzz About Sema4 Holdings Corp. Securities? Stay in the Know with Rosen Law Firm Picture this: it’s a brisk autumn day in New York, and you’re scrolling through the latest news on your phone. Suddenly, a headline catches your eye – “ROSEN, A TOP RANKED FIRM, Encourages Sema4 Holdings Corp….

Welcome to the Jungle: Kalera’s Wild Ride Let’s Talk About Money, Honey! So, did you hear the latest news from Kalera Public Limited Company? They just announced the pricing of their $8.84 million public offering! Talk about making it rain, right? As a company that specializes in vertical farming, they’re definitely planting the seeds for…

Rain Therapeutics: Advancing Precision Oncology Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium NEWARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53,…

Kaspersky launches a new online cybersecurity training for ‘Mobile Malware Reverse Engineering’ experts Woburn, MA, Oct. 26, 2022 (GLOBE NEWSWIRE) Developed by Kaspersky experts, the company’s new ‘Mobile Malware Reverse Engineering’ course helps upgrade any security team’s ability to counter various cyber threats caused for business by smartphones. The new learning program helps to develop…

Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpe… First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC Preclinical data support potential to address ~45% of HNSCC tumors that harbor HRAS overexpression and/or PIK3CA mutation SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE)…

Hi Traders! NZDJPY short term forecast follow up and update is here On September 14th I shared this “NZDJPY Technical Analysis And Short Term Forecast” post in our blog. In this post, let’s do a recap of this setup and see how it has developed now. If you would like to learn more about the…

Welcome to the Jungle: Navigating Securities Claims with Rosen Law Firm Oct. 19, 2022: A Globe Newsflash! Strap in, folks! Prepare for a wild ride as we delve into the latest buzz surrounding Enviva Inc. (NYSE: EVA) and the investigations underway by the esteemed Rosen Law Firm. Hold on to your hats! Picture this: you’re…